Atherosclerosis is hardening of artery due to the saturation of plaque inside the artery. The artery becomes narrow due to the development of plaque which eventually decreases the flow of blood to body parts. This further leads to elasticity loss of the walls of the arteries. Endothelium cells lined in thin layer which form the wall of arteries. Smoking, high cholesterol, and high blood pressure causes damage of endothelium which ultimately leads to atherosclerosis.
MARKET DYNAMICS
Rising geriatric population, and obesity, adoption of unhealthy diets leading to the incidence of high cholesterol, tobacco smoking, high body mass index, sedentary lifestyles, and hypertension are driving the Atherosclerosis Therapeutics market.
MARKET SCOPE
The "Global Atherosclerosis Therapeutics Market Analysis to 2028" is a specialized and in-depth study of the medical device industry with a special focus on the global market trend analysis. The report aims to provide an overview of Atherosclerosis Therapeutics market with detailed market segmentation by type, end user, and geography. The global Atherosclerosis Therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Atherosclerosis Therapeutics market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global Atherosclerosis Therapeutics market is segmented on the type, end user. Based on type, the market is segmented into Anti-platelet medications, Cholesterol lowering medications, Beta blockers, Angiotensin-converting enzyme (ACE) inhibitors, Calcium channel blockers, Others. Based on end user, the market is segmented into Hospital, Ambulatory Surgical Centers, Others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Atherosclerosis Therapeutics market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Atherosclerosis Therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Atherosclerosis Therapeutics market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Atherosclerosis Therapeutics market in these regions.
MARKET PLAYERS
The report covers key developments in the Atherosclerosis Therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Atherosclerosis Therapeutics market are anticipated to lucrative growth opportunities in the future with the rising demand for Atherosclerosis Therapeutics market in the global market. Below mentioned is the list of few companies engaged in the Atherosclerosis Therapeutics market.
The report also includes the profiles of key Atherosclerosis Therapeutics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Novartis AG
- Merck and Co., Inc.
- Sanofi
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Isis Pharmaceuticals, Inc.
- Anthera Pharmaceuticals
- Bayer AG
- Johnson and Johnson
- Cardium Therapeutics
- AstraZeneca Plc
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.